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The incidence of cardiogenic shock in community studies has not decreased significantly over time.
Despite decreasing mortality rates associated with increasing utilisation of revascularisation, shock
remains the leading cause of death for patients hospitalised with acute myocardial infarction (MI).
Although shock often develops early after MI onset, it is typically not diagnosed on hospital pres-
entation. Failure to recognise early haemodynamic compromise and the increased early use of
hypotension inducing treatments may explain this observation.
Recently, a randomised trial has demonstrated that early revascularisation reduces six and 12
month mortality.1 2 The current American College of Cardiology/American Heart Association
(ACC/AHA) guidelines recommend the adoption of an early revascularisation strategy for patients
< 75 years of age with cardiogenic shock.3 In this article, we review the incidence, aetiology, pre-
vention, and recognition of shock, as well as its management.
c INCIDENCE
The extent of myocardial salvage from reperfusion treatment decreases exponentially with time to
re-establishing coronary flow. Unfortunately, there has been little progress in reducing time to
hospital presentation over the past decade,4 and this perhaps accounts for the stagnant incidence
of cardiogenic shock in community studies (7.1%).5 Cardiogenic shock also complicates non-ST
elevation acute coronary syndromes. The incidence of shock in the PURSUIT trial was 2.9%
(1995–97),6 similar to the 2.5% incidence reported in the non-ST elevation arm of the GUSTO II-B
trial (1994–95).7 A number of strategies that centre on reducing the time to effective treatment may
help decrease the incidence of shock. These include public education to decrease the time to hos-
pital presentation, triage and early transfer of high risk patients to selected centres, and early pri-
mary percutaneous coronary intervention (PCI) or rescue PCI for failed thrombolysis in high risk
patients.
PREDICTING AND PREVENTING SHOCK
The onset of cardiogenic shock in a patient following ST elevation MI heralds a dismal in-hospital
prognosis. The 7.2% of patients developing shock in the GUSTO-I trial accounted for 58% of the
overall deaths at 30 days.8 Similarly, the 30 day death rates with non-ST elevation MI cardiogenic
shock in the PURSUIT and GUSTO-II b databases were 66% and 73%, respectively. Even with early
revascularisation, almost 50% die at 30 days. The prevention of shock is therefore the most effec-
tive management strategy. The opportunity for prevention is substantial, given the observation that
only a minority of patients (10–15%) present to the hospital in cardiogenic shock. Whether due to
pump failure or a mechanical cause, shock is predominantly an early in-hospital complication in
the ST elevation MI setting. The median time post-MI for occurrence of shock in the randomised
SHOCK trial was 5.0 (interquartile range 2.2–12) hours. Similarly, median time from MI onset to
development of shock in the SHOCK registry was 6.0 (1.8–22.0) hours, and median time from hos-
pital admission was 4 hours. Shock complicating unstable angina/non-Q MI occurs at a later time
period. In the GUSTO-IIb trial shock was recognised at a median of 76.2 (20.6–144.5) hours for
non-ST elevation MI compared to 9.6 (1.8–67.3) hours with ST elevation MI (p < 0.001), and
median time to shock in the non-ST elevation PURSUIT trial was 94.0 (38–206) hours.
A primary goal in preventing shock should be an effort to reduce the large proportion of patients
presenting with acute ST elevation MI who do not receive timely reperfusion treatment. Successful
early reperfusion of the infarct related coronary artery while maintaining integrity of the
downstream microvasculature limits ongoing necrosis, salvages myocardium, and may prevent the
development of shock in many vulnerable patients. In-hospital development of shock often follows
failed thrombolysis or successful thrombolysis followed by evidence of recurrent MI (ST
re-elevation), infarct extension (ST elevation in new leads), and recurrent ischaemia (new ST
depression). These complications may be significantly reduced by a primary PCI strategy. Currently,
a minority of hospitals in the USA and an even smaller proportion worldwide possess the
infrastructure and personnel to perform primary PCI effectively.
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Recognising patients at highest risk for development of
shock may facilitate the early transfer of high risk patients
before onset of haemodynamic instability. Early referral of
high risk patients for rescue angioplasty in the setting of
thrombolytic failure may also prove beneficial.
A number of scoring systems using predictive models for
the development of shock have been reported to aid with this
decision strategy. In the GUSTO-I study, age, systolic blood
pressure, heart rate, and presenting Killip class accounted for
> 85% of the predictive information. The same four variables
were significant in the GUSTO III population and accounted
for > 95% of the predictive information, with a validated con-
cordance index of 0.796.9 Major predictors of shock in the
PURSUIT population included age, systolic blood pressure, ST
depression on presenting ECG, heart rate, height, enrolling
MI, and rales on physical examination. Although these scoring
systems can be useful, the limitations of these databases need
to be stressed. Patients enrolled in randomised clinical trials
are themselves selected. Furthermore, positive predictive
value for a patient with maximum attainable scores in the
GUSTO-I and PURSUIT model are only 50% and 35%,
respectively.10
CLINICAL RECOGNITION
Treatment cannot be initiated unless the clinical entity is rec-
ognised. Cardiogenic shock is characterised by inadequate tis-
sue perfusion in the setting of adequate intravascular volume.
Specifically, shock in the peri-infarction setting is defined as
sustained hypotension (systolic blood pressure < 90 mm Hg
for > 30 minutes), accompanied by signs of peripheral hypo-
perfusion (altered mental status, cool peripheries, oliguria).
This clinical entity is unresponsive to fluid resuscitation alone,
with a cardiac index < 2.2 l/min/m2. Subjects requiring phar-
macologic or mechanical circulatory support to maintain
blood pressure are also included in this category. However,
there is a wide spectrum of clinical symptoms, signs, and
haemodynamic findings and variability in the severity of
shock. It should be diagnosed in all patients exhibiting signs
of inadequate tissue perfusion irrespective of blood pressure.
Some patients, particularly those with anterior MI, develop
signs of end organ hypoperfusion in the setting of unsup-
ported blood pressure measurements > 90 mm Hg. The urine
output is typically low and the heart rate > 90 beats per
minute. This “pre-shock” presentation is associated with a
high risk of in-hospital morbidity and mortality (43%).11
When the physician fails to recognise that the tachycardia is
caused by a pronounced reduction in stroke volume and
therefore administers β blockers, frank shock may be precipi-
tated.
In the SHOCK trial registry, 64% of patients presented typi-
cally with hypotension, evidence of ineffective cardiac output
(resting tachycardia, altered mental status, oliguria, cool
peripheries), and pulmonary congestion.12 A substantial
minority (28%) presented with evidence of hypoperfusion in
the absence of pulmonary congestion—the “silent lung” syn-
drome. These latter patients have an equal distribution of
anterior (50%) and non-anterior index infarctions (50%) with
pulmonary capillary wedge pressure in the range of
21.5±6.7 mm Hg. Inexperienced clinicians may inappropri-
ately treat such patients with large fluid boluses akin to the
management of hypotension with right ventricular
infarction.13 14 Unadjusted in-hospital mortality for this group
in the SHOCK registry exceeded that for the classical presen-
tation (70% v 60%, p = 0.036), a difference that was
non-significant after adjustment. These data highlight the
clinical importance of the subjective signs of hypoperfusion
obtained on physical examination in this population. In the
GUSTO-I mortality model, altered sensorium (odds of dying
1.68, 95% confidence intervals (CI) 1.19 to 2.39), cold clammy
skin (odds of dying 1.68, 95% CI 1.15 to 2.46), and oliguria
(odds of dying 2.25, 95% CI 1.61 to 3.15) were associated with
an increased 30 day mortality independent of haemodynamic
variables.15
AETIOLOGY
There are several possible causes of cardiogenic shock in the
setting of MI–left ventricular dysfunction, right ventricular
dysfunction, and mechanical complications (fig 1). Recogni-
tion of shock should immediately lead to a quest for its cause.
A combination of the history, physical findings, ECG, and a
screening echocardiogram (table 1) will enable the clinician to
arrive quickly at an accurate diagnosis. A right heart
catheterisation is often not necessary for diagnosis and need
only be performed when there is continued doubt or to guide
management when shock does not rapidly resolve. Predomi-
nant left ventricular pump failure in the setting of a large MI
is the most common aetiology. Ventricular septal rupture,
severe mitral regurgitation, cardiac rupture, and tamponade
should be excluded and haemorrhagic shock considered,
especially in the elderly. Although the typical findings of
significant right ventricular infarction are hypotension, clear
lung fields, and jugular venous distension, severe right
ventricular dysfunction (with or without excess fluid admin-
istration) may result in left ventricular compromise caused by
right ventricular distension and septal shift, resulting in clini-
cal evidence of pulmonary congestion. Systolic anterior
motion of the anterior mitral leaflet causing left ventricular
outflow tract obstruction in the MI setting has also been
reported. Other masqueraders in this situation include aortic
dissection and massive pulmonary embolism, which should be
considered in the appropriate clinical context. The latter
includes discordance between extent of ECG and haemody-
namic abnormalities—that is, mild to moderate ECG abnor-
malities in the setting of severe haemodynamic derangement.
MANAGEMENT OF CARDIOGENIC SHOCK CAUSED
BY PREDOMINANT LEFT VENTRICULAR FAILURE
Reports of dramatic declines in mortality with early revascu-
larisation for cardiogenic shock began to emerge in the late
1980s.16–18 Dedicated investigators in selected centres reported
these single centre observations which were, however, prone
to selection and publication bias. Randomised clinical trials
testing the superiority and generalisability of an early
Trial acronyms
DIGAMI: Diabetes mellitus Insulin Glucose infusion in Acute
Myocardial Infarction
FTT: Fibrinolytic Therapy Trialists
GUSTO: Global Utilization of Streptokinase and Tissue
plasminogen activator for Occluded coronary arteries
PURSUIT: Platelet glycoprotein IIb/IIIa in Unstable angina:
Receptor Suppression Using Integrilin Therapy
SHOCK: SHould we emergently revascularize Occluded
Coronaries for cardiogenic shocK ?




revascularisation strategy were clearly warranted and the
National Heart, Lung, and Blood Institute funded the SHOCK
trial in the USA, while the SMASH trial in Switzerland evalu-
ated the same issue.19 20 While SMASH failed to recruit an
adequate number of patients, SHOCK reported an increase in
30 day survival from 46.7% to 56.0% by the adoption of an
early revascularisation strategy, but this absolute 9% differ-
ence did not reach significance (p = 0.11). On follow up, the
survival difference in favour of the early revascularisation
strategy became larger and significant at six months (36.9% v
49.7%, p = 0.027) and one year (33.6% v 46.7%) for an abso-
lute reduction of 13.2% (95% CI 2.2% to 24.1%, p < 0.03). The
Kaplan-Meier survival curves for the early revascularisation
and initial medical stabilisation arms are illustrated in fig 2.
There were 10 prespecified subgroup variables examined,
including sex, age, prior MI, hypertension, diabetes, anterior
MI, early or late shock, and transfer or direct admission status.
A benefit of early revascularisation was demonstrated for all
subgroups except for the elderly. Age > 75 versus < 75 years
interacted significantly with treatment effect at 30 days, six
months, and one year. The benefit of early revascularisation
was large for those < 75 years at 30 days (41.4% v 56.8%, 95%
CI −27.8% to −3.0%), and six months (44.9% v 65.0%, 95% CI
−31.6% to −7.1%) and was not apparent for the elderly (see
below). An increased utilisation of revascularisation was also
associated with improved outcome in the GUSTO-I thrombo-
lytic trial and favourable outcomes in recent registries.21 22 An
algorithm for the management of cardiogenic shock is
outlined in fig 3.
Step 1: immediate resuscitation measures
The goal is to prevent devastating end organ injury while the
patient is being transported for definitive treatment. Mainte-
nance of adequate mean arterial pressure to prevent adverse
neurologic and renal sequelae is vital. Dopamine or noradren-
aline (norepinephrine), depending on the degree of hypoten-
sion, should be initiated promptly to raise mean arterial pres-
sure and be maintained at the minimum dose required.
Dobutamine may be combined with dopamine at moderate
doses or used alone for a low output state without frank hypo-
tension. Intra-aortic balloon counterpulsation should be initi-
ated before transportation when facilities are available.
Arterial blood gas and oxygen saturation should be monitored
with early institution of continuous positive airway pressure
or mechanical ventilation as needed. The ECG should be
monitored continuously, and defibrillating equipment, intra-
venous amiodarone, and lidocaine should be readily available.
(Thirty three per cent of patients in the early revascularisation
arm of the SHOCK trial had cardiopulmonary resuscitation,
sustained ventricular tachycardia or ventricular fibrillation
before randomisation.) Transcutaneous pacing electrodes as
well as provisions for temporary transvenous pacing should be
placed at the patient’s bedside. Aspirin and full dose heparin
should be administered. For ST elevation MI requiring trans-
fer for angiography, we recommend intra-aortic balloon pump
(IABP) placement at the local hospital when possible. A fibri-
nolytic agent should be initiated in patients with ST elevation
MI if the anticipated delay to angiography is more than two
hours. Thirty five day mortality for patients with systolic blood
pressure < 100 mm Hg receiving thrombolysis in the FTT
meta-analysis was 28.9% compared to 35.1% with placebo.
This translates into 62 lives saved (95% CI 26 to 98, p < 0.001)
per 1000 patients treated.23 Augmentation of blood pressure
with an IABP in this situation may facilitate thrombolysis by
increasing coronary perfusion pressure. Similarly, raising
blood pressure (to 130 mm Hg systole) by using vasopressor
support has also shown synergism in experimental models,
but this increase is difficult to achieve in patients in shock. For
Figure 1 Aetiology of suspected cardiogenic shock in the
combined SHOCK trial registry and trial (total n = 1422, only first
232 trial patients are included). “Other” includes shock caused by
prior severe valvar disease, dilated cardiomyopathy, excess β
blockade/calcium channel blockade, haemorrhage, and procedural
complications. Aortic dissection, pulmonary embolism, and dynamic
subaortic outflow obstruction should also be considered. LVF, left
ventricular function; MR, mitral regurgitation; RVF, right ventricular

























Table 1 Usefulness of echocardiography in
cardiogenic shock
c Evaluate left ventricular function and myocardium at risk
c Evaluate remote myocardial segments
c Screen for ventricular septal rupture
c Screen for severe mitral regurgitation and proceed to
transoesophageal echocardiography as needed
c Look for tamponade/rupture
c Assess right ventricular function
c Look for aortic dissection
Figure 2 Kaplan-Meier curve showing 12 month survival in the
early revascularisation and initial medical stabilisation arms of the
SHOCK trial. Reproduced from Hochman et al,2 with permission of
the American Medical Association.
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non-ST elevation MI cardiogenic shock awaiting catheterisa-
tion, a glycoprotein IIb/IIIa inhibitor should be initiated.
Step 2: early definition of coronary anatomy
This is the pivotal step in the management of cardiogenic
shock resulting from predominant ischaemic pump failure.
Patients in a community hospital setting should be emer-
gently transferred/airlifted to an experienced designated
regional tertiary care facility. The referring and accepting phy-
sician as well as the critical care transport team should be in
constant communication to avoid delays in cardiac catheteri-
sation. Prophylactic IABP placement is recommended before
transfer and otherwise before angiography; radiocontrast use
should be minimised. Early reversal of hypotension with IABP
support serves as an excellent prognostic marker for survival,
but those who do or do not respond well to IABP both derive
benefit from early revascularisation. If a high quality echocar-
diogram has already been performed, a ventriculogram need
not be repeated. Shock is characterised by a high incidence of
triple vessel disease, left main disease, and impaired left ven-
tricular function.24 The mean (SD) left ventricular ejection
fraction for patients in the SHOCK trial and registry was 29
(11)% and 34 (14)%, respectively. The extent of ventricular
dysfunction and haemodynamic instability should be corre-
lated with coronary anatomy. An isolated circumflex lesion or
a right coronary lesion should rarely manifest as shock in the
absence of right ventricular infarction, left ventricular under-
filling, bradyarrhythmia or prior MI or cardiomyopathy. In
situations like this it is important for the clinician to immedi-
ately consider and exclude mechanical and other aetiologies of
cardiogenic shock.
Step 3: perform early revascularisation
Definition of anatomy should be followed rapidly by selection
of the modality of revascularisation. PCI will most often be the
treatment of choice. Glycoprotein IIb/IIIa antagonists and
stenting of the infarct related artery are indicated, although
trial data are lacking. Recent reports suggest an additive ben-
efit of stenting and glycoprotein IIb/IIIa antagonists in cardio-
genic shock similar to the remainder of the clinical spectrum
of PCI.25 However, if there is sluggish flow despite absence of
post-coronary angioplasty stenosis, we recommend waiting
until flow normalises before stenting. Stenting may exacer-
bate distal embolisation. Glycoprotein IIb/IIIa antagonists
may improve reflow. Intracoronary adenosine or nitroprusside
may be tried. There is no randomised clinical evidence to sup-
port multivessel angioplasty in this setting, and the decision to
perform angioplasty in the non-infarct related artery should
be individualised. In selected cases, with remote ischaemia,
Figure 3 Algorithm on management of cardiogenic shock following ST elevation myocardial infarction. AS, atrial stenosis; CABG, coronary
artery bypass graft; CAD, coronary artery disease; IABP, intra-aortic balloon pump; LAD, left anterior descending; LBBB, left bundle branch
block; LV, left ventricle; MR mitral regurgitation; MS, mitral stenosis; PTCA, percutaneous transluminol coronary angioplasty; RV, right ventricle;
VSR, ventricular septal rupture. Reproduced from Topol EJ (ed) Textbook of cardiovascular medicine, 2nd ed, with permission.
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non-infarct related artery critical stenosis, and lack of haemo-
dynamic improvement after infarct related artery PCI (with
IABP support), revascularisation of the non-infarct territory
may play a role. In patients with moderate three vessel disease,
emergent PCI of the infarct related artery with consideration
for later coronary artery bypass graft surgery (CABG) is
preferred based on the concern that distal embolisation in
non-infarct related artery segments is not tolerated in shock.
There are no trials randomising patients to PCI versus
CABG in the setting of cardiogenic shock. The safety and fea-
sibility of CABG in this situation is well documented. Severe
triple vessel and left main coronary artery disease with
severely impaired left ventricular function predominate in the
shock setting. Emergent CABG allows the opportunity to
achieve complete revascularisation and rectify severe mitral
regurgitation while cardiopulmonary bypass maintains sys-
temic perfusion. The SHOCK trial protocol recommended
emergency CABG for patients with left main or severe three
vessel disease. The in-hospital mortality rates with CABG in
the SHOCK trial and registry were the same as the outcomes
with PCI despite more severe coronary artery disease and
twice the rate of diabetes in patients who underwent CABG
(fig 4). We believe that CABG is underused in the shock
setting. When dictated by anatomy, we recommend emergent
CABG with pre-induction IABP support. The potential for
benefit with metabolic support in this situation is large but
remains formally untested in the shock setting.
Intra-aortic balloon counterpulsation support
Consistent with the current ACC/AHA guidelines, we recom-
mend early consideration of IABP placement for patients with
cardiogenic shock who are candidates for an aggressive strat-
egy. Although randomised controlled trial data are lacking,
benefit is seen across a number of observational databases.26–29
It provides excellent temporary haemodynamic support in
many patients.30 It must also be noted that in the randomised
SHOCK trial use of IABP was strongly recommended in both
the early revascularisation and conservative arm. IABP
utilisation was 87% in this trial and may have contributed to
the improved outcomes observed in both groups compared to
historical controls. The observed rates of IABP utilisation in
US sites increased from 35% in GUSTO-I to 47% in GUSTO-III
(p = 0.001).31 In contrast, utilisation at non-US sites in both
trials were low (7% and 10%, respectively). We believe that
IABP is currently underutilised in the setting of shock and
strongly recommend that community hospitals attempt to
develop an IABP programme so that treatment may be
initiated before transfer whenever possible.
ISSUES IN SHOCK MANAGEMENT
How should the elderly be treated?
Although there was no apparent benefit from an early revas-
cularisation strategy in patients aged > 75 years in the
SHOCK trial, the total number of patients in this subgroup
was small (n = 56). The 17% of 277 patients aged > 75 years
in the concomitant SHOCK registry who were selected for
early revascularisation appeared to derive benefit that was
similar to their younger counterparts, even after covariate
adjustment.32 We do not feel there is adequate evidence to cat-
egorically deny early revascularisation to the elderly. We use an
individualised approach to the elderly. A select group based on
prior functional status, “physiologic” age, comorbidity, prox-
imity of MI, duration of shock, and coronary anatomy may be
offered an early revascularisation strategy. In the absence of
contraindications, the remainder are treated with thrombo-
lysis with or without IABP, or comfort care alone for those
unlikely to benefit (see below). The very elderly often request
comfort care alone.
Is there a therapeutic window for emergency
revascularisation?
Early revascularisation should be considered as soon as possi-
ble following diagnosis of cardiogenic shock. The median time
from randomisation to revascularisation was 1.4 (0.6–2.8)
hours and the median time from MI to randomisation was 11
hours in the randomised SHOCK trial. However, it should be
noted that patients were eligible for the trial if shock was
diagnosed within 36 hours of index MI and randomisation
performed within 12 hours of shock onset. There was no sig-
nificant interaction between time from MI to randomisation
and treatment effect. Ongoing ischaemia and stuttering
necrosis are typical in the vicious cycle of ischaemia–
hypoperfusion that characterise shock. Unlike primary reper-
fusion treatment, the window of opportunity in this setting is
large. We recommend an early revascularisation strategy for
shock patients up to 48 hours post-index MI and up to 18
hours post-shock. Patients who are not revascularised within
18 hours of shock onset but survive the early phase with reso-
lution of shock should undergo coronary angiography. Revas-
cularisation should be performed based on standard post-MI
criteria—that is, triple vessel or left main disease or spontane-
ous or inducible ischaemia.
What is the quality of life?
Although the SHOCK trial showed that 13 lives were saved at
one year per 100 patients treated with an early revascularisa-
tion strategy, it was important to document that survivors had
an acceptable quality of life. It is reassuring that 83% of one
year survivors (n = 90) were in New York Heart Association
heart failure functional class I or II at 12 months.
Is care ever futile?
It is difficult to assess futility in the acute critical setting that
characterises cardiogenic shock. It is vital to establish
communication with the family as soon as the clinical entity is
recognised. The patient or surrogate should play a role in the
decision making process. Patients who require prolonged car-
diopulmonary resuscitation and sustain presumed anoxic
brain damage and those with other life shortening illnesses
are not candidates for aggressive care. Although cardiac index,
blood pressure, signs of hypoperfusion, and ejection fraction
are independently associated with outcome, the beneficial
effect of early revascularisation was noted across the spectrum
of subgroups, except the very elderly. Further research is
Figure 4 In-hospital mortality with percutaneous coronary
intervention (PCI) and coronary artery bypass graft surgery (CABG)
in the early revascularisation arm of the randomised SHOCK trial





























required to develop a risk score to identify other patients with
very poor outcomes despite early revascularisation. This may
enable effective resource utilisation in the future and prevent
heroic manoeuvres for patients unlikely to benefit.
MANAGEMENT OF MECHANICAL COMPLICATIONS
The utilisation of early reperfusion strategies has decreased
the incidence of mechanical complications post ST-elevation
MI.33 34 Overall incidence of ventricular septal rupture in the
GUSTO-I trial was 0.2% (84/41021) with a 30 day mortality of
73.8%.35 Although IABP may help achieve temporary haemo-
dynamic stability, prognosis following onset of haemodynamic
collapse is grim.36 The overall in-hospital mortality for
ventricular septal rupture complicated by cardiogenic shock in
the SHOCK registry was 87% (47/55) with an 81% (25/31)
surgical mortality. A significant number of patients will have
ventricular septal rupture without early evidence of circula-
tory collapse. Onset of circulatory collapse in this situation is
unpredictable, and a superior surgical outcome is realised
when emergent surgery is performed before the onset of car-
diogenic shock. In keeping with the ACC/AHA guidelines, we
recommend urgent surgery for our patients with newly diag-
nosed ventricular septal rupture. Similarly, all patients with
mechanical mitral regurgitation and subacute rupture should
be emergently considered for surgical intervention.
FUTURE DIRECTIONS
The role of L-NMMA, a selective nitric oxide inhibitor, is
promising in this setting.37 The utility of GIK (glucose, insulin,
and potassium) metabolic support for cardiogenic shock
patients is an intriguing but unanswered question. However,
we recommend intensive insulin treatment to normalise blood
glucose in those with elevated values. The DIGAMI study sug-
gested that this strategy was beneficial for acute MI patients.
In a study of intensive care unit patients, those with hypergly-
caemia who were randomised to intensive insulin had reduced
mortality rates.38
The role of selection of patients for wearable left ventricular
assist devices and their clinical utility in the setting of shock
following MI needs to be explored. Patients who are
candidates for cardiac transplantation should receive bridging
left ventricular assist devices.
CONCLUSION
Early recognition and transfer of high risk patients and adop-
tion of a primary PCI strategy may decrease the incidence of
cardiogenic shock. Establishing the aetiology of shock and
early definition of coronary anatomy in the setting of pump
failure are crucial. We recommend urgent revascularisation
supported by IABP for patients aged < 75 years in cardiogenic
shock caused by pump failure. A selective approach is
advocated for the elderly. Regional care centres that are expe-
rienced in the management of shock should be designated and
protocols developed for rapid transport of critically ill patients.
Further research is needed in the areas of pharmacologic and
mechanical haemodynamic support, refinement of revascu-
larisation strategies, and outcome modelling.
. . . . . . . . . . . . . . . . . . . . .
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